The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder / Konstantinos N. Fountoulakis en European Neuropsychopharmacology, Año 2015 - Vol. 25 - No.3 (Marzo)

Público ISBD [artículo]  inEuropean Neuropsychopharmacology > Año 2015 - Vol. 25 - No.3 (Marzo) . - pp. 335-342 Título : The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder Tipo de documento: texto impreso Autores: Konstantinos N. Fountoulakis, Autor ; Maria Gazouli, Autor ; John R. Kelsoe, Autor Fecha de publicación: 2021 Artículo en la página: pp. 335-342 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Lurasidona, Depresión bipolar, Neurobiología, Modelos biologicos, Trastorno bipolar Resumen: The treatment of bipolar depression is one of the most challenging issues in contemporary psychiatry. Currently only quetiapine, the olanzapine–fluoxetine combination and recently lurasidone are officially FDA-approved against this condition. Link: ./index.php?lvl=notice_display&id=26813 [artículo] The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder [texto impreso] / Konstantinos N. Fountoulakis, Autor ; Maria Gazouli, Autor ; John R. Kelsoe, Autor . - 2021 . - pp. 335-342. Idioma : Inglés (eng) Idioma original : Inglés (eng) in European Neuropsychopharmacology > Año 2015 - Vol. 25 - No.3 (Marzo) . - pp. 335-342 Palabras clave: Lurasidona, Depresión bipolar, Neurobiología, Modelos biologicos, Trastorno bipolar Resumen: The treatment of bipolar depression is one of the most challenging issues in contemporary psychiatry. Currently only quetiapine, the olanzapine–fluoxetine combination and recently lurasidone are officially FDA-approved against this condition. Link: ./index.php?lvl=notice_display&id=26813

---

1 (1 - 1 / 1)